MedTrace Logo

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

NCT03970122 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-06-02

No results posted yet for this study

Summary

The study will comprise primarily a single-ascending dose (SAD) escalation component.

Conditions

  • Healthy Volunteers

Interventions

DRUG

GFB-887

IMP

DRUG

Placebo

Matching

Sponsors & Collaborators

  • Goldfinch Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeanelle Kam, MD · Covance Clinical Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2020-03-04
Completion
2020-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03970122 on ClinicalTrials.gov